ISONOVA
LIVE

Serial Number

98510322

Owner

Isomorphic Labs Limited

Attorney

Lindsay B. Allen

Filing Date

Apr 19, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ISONOVA Trademark

Serial Number: 98510322

ISONOVA is a trademark filed by Isomorphic Labs Limited on April 19, 2024. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Isomorphic Labs Limited (12 trademarks)

280 Bishopsgate
London EC2M4RB , GB

Entity Type: 99

Trademark Details

Filing Date

April 19, 2024

Registration Date

Not Registered

Published for Opposition

January 7, 2025

Goods & Services

Downloadable software for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; downloadable computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for predicting protein structure, discovering drugs, designing drug candidates, biologic product development, and pharmaceutical product development; downloadable computer software, computer programs and computer software algorithms for manipulating received or inputted data generated in a virtual space in connection with artificial intelligence methods, machine learning methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, and predictive assistance technologies, for protein structure prediction, l drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; downloadable computer software for conducting therapeutic product research and development; downloadable computer software for discovering, optimizing and developing drugs; downloadable computer software for designing and developing drug candidates

Software as a service (SAAS) services featuring software for protein structure prediction, drug discovery, drug candidate design, biological product development, and pharmaceutical product development; software as a service (SAAS) services featuring software using artificial intelligence, machine learning, deep learning, or reinforcement learning for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; platform as a service (PaaS) services featuring software for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; platform as a service (PaaS) services featuring software using artificial intelligence, machine learning, deep learning, and reinforcement learning for protein structure prediction, drug discovery, development of biologic materials, development of biologic products, and pharmaceutical product development; advanced product research, design and development in the field of artificial intelligence for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; research and development in the fields of artificial intelligence, machine learning, deep learning, and reinforcement learning technologies for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; technology research in the field of artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; providing online, non-downloadable computer software platforms for protein structure prediction, drug discovery, drug candidate design, biologic material development, , and pharmaceutical product development; providing online, non-downloadable computer software platforms using artificial intelligence, machine learning, deep learning, or reinforcement learning for protein structure prediction, drug discovery, drug candidate design, biological produce development, and pharmaceutical product development; testing of computing methods, computer software algorithms, computer software, and computer hardware for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; scientific, pharmaceutical, biotech, medical, and artificial intelligence research; scientific research in the field of computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for medical research, pharmaceutical research, biotech research, protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; product research and development; medical, pharmaceutical, biotech, and scientific research in the field of protein structure prediction, drug discovery, drug candidate design, biologic product development, pharmaceutical product development, and computational biology; scientific and technological services, namely, scientific research in the fields of analytics and data mining, data analysis, data transformation, data visualization, statistical analysis, artificial intelligence, machine learning, virtual reality, science, chemistry, medicinal chemistry, physics, biology, and digital biology, all for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer aided data analysis for scientific research purposes in the fields of artificial intelligence, machine learning, deep learning, reinforcement learning, building neural networks, data tree search, high performance computing, distributed computing, cloud computing, analytics and data mining, virtual reality, augmented reality, chemistry, medicinal chemistry, physics, biology, and digital biology, all for protein structure prediction, drug discovery, drug candidate design, biologic product development, and pharmaceutical product development; computer modelling services; technical or scientific services for the analysis of compositions of matter; technical consulting in the field of pharmaceutical studies; drug discovery, drug design, optimization and development services; research and development of therapeutic products; drug discovery, optimization and development services; medical and scientific services in the field of pharmaceuticals, namely, therapeutic and diagnostic candidate design services

Filing History

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 1, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 14, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 14, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 14, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 14, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 14, 2024 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 12, 2024 GNRN
NON-FINAL ACTION E-MAILED
Nov 12, 2024 GNRT
NON-FINAL ACTION WRITTEN
Nov 12, 2024 CNRT
ASSIGNED TO EXAMINER
Nov 4, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 7, 2024 NWOS
NEW APPLICATION ENTERED
Apr 19, 2024 NWAP